[go: up one dir, main page]

CN104177361B - An ASA-type enzyme inhibitor based on auxin-regulated gene GH3 and preparation method thereof - Google Patents

An ASA-type enzyme inhibitor based on auxin-regulated gene GH3 and preparation method thereof Download PDF

Info

Publication number
CN104177361B
CN104177361B CN201410422288.1A CN201410422288A CN104177361B CN 104177361 B CN104177361 B CN 104177361B CN 201410422288 A CN201410422288 A CN 201410422288A CN 104177361 B CN104177361 B CN 104177361B
Authority
CN
China
Prior art keywords
preparation
asa
add
reaction
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201410422288.1A
Other languages
Chinese (zh)
Other versions
CN104177361A (en
Inventor
杨庆华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hefei University of Technology
Original Assignee
Hefei University of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hefei University of Technology filed Critical Hefei University of Technology
Priority to CN201410422288.1A priority Critical patent/CN104177361B/en
Publication of CN104177361A publication Critical patent/CN104177361A/en
Application granted granted Critical
Publication of CN104177361B publication Critical patent/CN104177361B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种基于植物生长素调节基因GH3的ASA型酶抑制剂及其制备方法,其中酶抑制剂的结构式为:R为苯乙基或萘基。本发明的酶抑制剂对于GH3-6的IC50分别为16.00±1.80、0.45±0.02μM,具有较好的酶抑制活性,在农药等领域显示潜在的应用前景。本发明酶抑制剂的制备方法简单,无需特殊反应条件,在常温常压下反应,后处理简便,产物收率较高。The invention discloses an ASA-type enzyme inhibitor based on the auxin-regulated gene GH3 and a preparation method thereof, wherein the structural formula of the enzyme inhibitor is: R is phenethyl or naphthyl. The IC 50 of the enzyme inhibitor of the present invention for GH3-6 is 16.00±1.80 and 0.45±0.02 μM respectively, has good enzyme inhibitory activity, and shows potential application prospects in fields such as pesticides. The preparation method of the enzyme inhibitor of the present invention is simple, does not need special reaction conditions, reacts at normal temperature and pressure, has simple post-treatment and high product yield.

Description

一种基于植物生长素调节基因GH3的ASA型酶抑制剂及其制备方法An ASA-type enzyme inhibitor based on auxin-regulated gene GH3 and preparation method thereof

一、技术领域1. Technical field

本发明涉及一种酶抑制剂及其制备方法,具体地说是一种基于植物生长素调节基因GH3的ASA型酶抑制剂及其制备方法。The invention relates to an enzyme inhibitor and a preparation method thereof, in particular to an ASA-type enzyme inhibitor based on the auxin regulating gene GH3 and a preparation method thereof.

二、背景技术2. Background technology

植物生长素是最早发现的植物激素,它的化学本质是一类没有结构特征的有机小分子物质,包括水杨酸(SA)、茉莉酸(JA)以及最有代表性的2-吲哚乙酸(IAA)等,主要集中在植物的嫩芽、顶端、根尖等具有生长优势的部位。它们对细胞的分裂与增殖、组织与器官的分化、开花与果实成熟、种子的萌发及休眠等有重要的生理调节作用。植物生长素对于植物的生理具有双重调节作用:在低浓度时,它可以促进嫩芽生长,根尖发达;在高浓度时会抑制植物顶端、根系的生长,甚至会导致植物死亡等。Auxin is the earliest discovered plant hormone. Its chemical essence is a class of organic small molecules without structural characteristics, including salicylic acid (SA), jasmonic acid (JA) and the most representative 2-indoleacetic acid. (IAA), etc., are mainly concentrated in the plant's shoots, tops, root tips and other parts that have growth advantages. They play an important role in physiological regulation of cell division and proliferation, tissue and organ differentiation, flowering and fruit ripening, seed germination and dormancy. Auxin has a dual regulatory effect on the physiology of plants: at low concentrations, it can promote the growth of shoots and develop root tips; at high concentrations, it can inhibit the growth of plant tops and roots, and even cause plant death.

目前,对于植物生长素调节基因研究较彻底的是GH3基因家族。在拟南芥基因组中,目前已经发现19个基因成员,分别命名为GH3-1、GH3-2、GH3-3、……GH3-19等。已经有证据表明,GH3基因编码的蛋白质具有催化水杨酸(SA)、吲哚乙酸(IAA)、茉莉酸(JA)的腺苷化作用,从而可以调节这些植物激素的体内水平。另外,研究还发现它们还能催化IAA与各种氨基酸的连接反应,以IAA-X(X=Ala、Asp、Glu、Leu等)非活性体的形式存储在体内,从而达到调节IAA和相关氨基酸在体内水平的目的。具体过程如下式所示:At present, the GH3 gene family is the most thorough research on auxin-regulated genes. In the Arabidopsis genome, 19 gene members have been found so far, named GH3-1, GH3-2, GH3-3, ... GH3-19 and so on. It has been shown that the protein encoded by the GH3 gene can catalyze the adenylation of salicylic acid (SA), indoleacetic acid (IAA), and jasmonic acid (JA), thereby regulating the levels of these plant hormones in vivo. In addition, studies have also found that they can also catalyze the connection reaction between IAA and various amino acids, and store them in the body in the form of inactive forms of IAA-X (X=Ala, Asp, Glu, Leu, etc.), so as to achieve the regulation of IAA and related amino acids. purpose at the in vivo level. The specific process is shown in the following formula:

IAA的生理腺苷化过程是:2-吲哚乙酸(IAA)在三磷酸腺苷(ATP)的作用下,生成其活化中间体-腺苷单磷酸酯(IAA-AMP),同时脱去一分子焦磷酸(PPi);然后各种氨基酸与IAA-AMP反应,形成吲哚乙酸与氨基酸(aa)的复合体(IAA-aa),它是IAA的非活性体贮存形式,能调节IAA在植物体内的激素水平,从而对植物的生长调节起到重要作用。The physiological adenylation process of IAA is: under the action of adenosine triphosphate (ATP), 2-indoleacetic acid (IAA) generates its activated intermediate - adenosine monophosphate (IAA-AMP), and at the same time removes a molecule of pyrophosphate (PPi); then various amino acids react with IAA-AMP to form a complex (IAA-aa) of indole acetic acid and amino acid (aa), which is the inactive storage form of IAA and can regulate the hormone of IAA in plants level, which plays an important role in the regulation of plant growth.

三、发明内容3. Contents of the invention

本发明旨在提供一种基于植物生长素调节基因GH3的ASA型酶抑制剂及其制备方法,所要解决的技术问题是通过分子设计遴选得到对GH3基因具有较好的酶抑制活性的化合物。The present invention aims to provide an ASA-type enzyme inhibitor based on auxin-regulating gene GH3 and a preparation method thereof. The technical problem to be solved is to select a compound with better enzyme-inhibiting activity on GH3 gene through molecular design.

本发明通过分子设计制备了系列基于ASA中间体的各种ASA-羧酸复合物(ASA-ca),它们具有与IAA-AMP类似的腺苷结构。The present invention prepares a series of various ASA-carboxylic acid complexes (ASA-ca) based on ASA intermediates through molecular design, and they have an adenosine structure similar to IAA-AMP.

本发明基于植物生长素调节基因GH3的ASA型酶抑制剂的结构式为:The present invention is based on the structural formula of the ASA-type enzyme inhibitor of the auxin-regulated gene GH3:

R为苯乙基或萘基,下同。R is phenethyl or naphthyl, the same below.

本发明基于植物生长素调节基因GH3的ASA型酶抑制剂的制备方法如下:The preparation method of the ASA type enzyme inhibitor based on the auxin regulating gene GH3 of the present invention is as follows:

1)羧基的活化1) Activation of the carboxyl group

在氮气保护下,将羧酸和羧基活化剂溶于有机溶剂中,溶液澄清,室温下密闭反应1-2h,得到中间体1,制备得到的中间体1不用分离即可直接用于下一步反应。Under the protection of nitrogen, dissolve the carboxylic acid and the carboxyl activator in an organic solvent, the solution is clear, and react in a closed manner at room temperature for 1-2 hours to obtain intermediate 1, which can be directly used in the next step without separation .

所述羧酸和所述羧基活化剂之间的摩尔比为1:1.1-1.3;The molar ratio between the carboxylic acid and the carboxyl activator is 1:1.1-1.3;

所述羧酸为苯丙酸或萘甲酸等;Described carboxylic acid is phenylpropionic acid or naphthoic acid etc.;

所述羧基活化剂为羰基二咪唑(CDI)、N-羟基琥珀酰亚胺(NHS)、1-(3-二甲基氨基丙基)-3-乙基碳化二亚胺盐酸盐(EDC.HCl)或二环己基碳二亚胺(DCC)等;The carboxyl activator is carbonyldiimidazole (CDI), N-hydroxysuccinimide (NHS), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC .HCl) or dicyclohexylcarbodiimide (DCC), etc.;

所述有机溶剂为无水乙腈、N,N-二甲酰胺(DMF)、二甲亚砜(DMSO)或干燥的二氯甲烷等;The organic solvent is anhydrous acetonitrile, N,N-diformamide (DMF), dimethyl sulfoxide (DMSO) or dry dichloromethane, etc.;

所述中间体1的结构式为:The structural formula of the intermediate 1 is:

2)偶联2) Coupling

向步骤1)制得的反应液中加入ASA中间体,溶液变浑浊,在冰水浴的条件下向反应液中加入1,8-二氮杂环[5.4.0]十一碳-7-烯(DBU),溶液变澄清,室温密闭条件下反应8-12h,反应结束后减压蒸馏脱除溶剂,然后加入CHCl3溶解,再加入质量浓度3%的柠檬酸溶液洗涤,分离收集有机相,有机相依次用水和饱和食盐水洗涤后经无水硫酸钠干燥,减压蒸馏脱除CHCl3,随后过硅胶柱(以体积比CHCl3/MeOH=10-12:1作为流动相)分离得到中间体2;Add ASA intermediate to the reaction solution prepared in step 1), the solution becomes turbid, and add 1,8-diazacyclo[5.4.0]undec-7-ene to the reaction solution under the condition of ice-water bath (DBU), the solution becomes clear, and reacts for 8-12h under airtight conditions at room temperature. After the reaction finishes, the solvent is distilled off under reduced pressure, then CHCl is added for dissolving, then the citric acid solution of mass concentration 3 % is added for washing, and the organic phase is separated and collected. The organic phase was washed with water and saturated brine successively, dried over anhydrous sodium sulfate, and CHCl 3 was removed by distillation under reduced pressure, and then separated on a silica gel column (with a volume ratio of CHCl 3 /MeOH=10-12:1 as the mobile phase) to obtain intermediate body 2;

反应液中中间体1、ASA中间体以及DBU之间的摩尔比为1:1:1.8-2.5。The molar ratio of intermediate 1, ASA intermediate and DBU in the reaction liquid is 1:1:1.8-2.5.

所述ASA中间体的结构式为:The structural formula of the ASA intermediate is:

所述中间体2的结构式为:The structural formula of the intermediate 2 is:

3)脱保护基3) deprotection group

将中间体2加入脱保护基试剂溶液中,室温下反应1.5-2.5h,反应结束后减压脱除溶剂,以丙酮重结晶后得到目标产物;Add intermediate 2 into the deprotecting group reagent solution, react at room temperature for 1.5-2.5 hours, remove the solvent under reduced pressure after the reaction, and obtain the target product after recrystallization with acetone;

在脱保护基反应过程中,脱保护基试剂的添加量是大大过量的,一般脱保护基试剂与中间体2的摩尔量之比控制在150-300:1。During the deprotection reaction process, the addition amount of the deprotection reagent is greatly excessive, and generally the molar ratio of the deprotection reagent to the intermediate 2 is controlled at 150-300:1.

所述脱保护基试剂溶液为质量浓度80%的HCOOH水溶液、质量浓度的5-10%盐酸溶液或三氟乙酸(TFA)等。The deprotection group reagent solution is 80% HCOOH aqueous solution, 5-10% hydrochloric acid solution or trifluoroacetic acid (TFA) and the like.

所述以丙酮重结晶的具体过程如下:Described concrete process with acetone recrystallization is as follows:

将减压脱除溶剂后得到的白色固体加入烧瓶中,加入丙酮,加热至回流状态并不断添加新的丙酮,直至白色固体不再溶解,趁热过滤,滤液在冰水浴的条件下静置结晶,过滤、洗涤并干燥后即得目标产物。Put the white solid obtained after removing the solvent under reduced pressure into a flask, add acetone, heat to reflux and continuously add new acetone until the white solid is no longer dissolved, filter while it is hot, and the filtrate crystallizes in an ice-water bath , filtered, washed and dried to obtain the target product.

本发明的反应路线如下式所示:Reaction scheme of the present invention is shown in following formula:

本发明使用的ASA中间体具有与IAA-AMP复合物类似的分子结构,其中的腺苷结构能够被GH3基因编码的酶所强烈特异性识别。The ASA intermediate used in the present invention has a molecular structure similar to that of the IAA-AMP complex, and the adenosine structure in it can be strongly and specifically recognized by the enzyme encoded by the GH3 gene.

【酶抑制活性测定】【Determination of enzyme inhibitory activity】

经1HNMR、元素分析确定产品纯度以后,发明人测试了所制备的目标产物对GH3-6酶活性抑制效果。具体测试步骤如下:After confirming the purity of the product by 1HNMR and elemental analysis, the inventor tested the inhibitory effect of the prepared target product on GH3-6 enzyme activity. The specific test steps are as follows:

1)酶催化反应:向2mL的离心管中依次加入Tris-HCl(pH8.0)、MgCl2、ATP、IAA、天冬氨酸、酶抑制剂以及GH3-6,控制离心管内液体的总体积为1mL,离心管中Tris-HCl(pH8.0)的浓度为100mM,MgCl2的浓度为5mM、ATP的浓度为500μM、IAA的浓度为100μM、天冬氨酸的浓度为1mM、GH3-6的浓度为14μg/mL,在30℃的条件下培养10min;1) Enzyme-catalyzed reaction: Add Tris-HCl (pH8.0), MgCl 2 , ATP, IAA, aspartic acid, enzyme inhibitors and GH3-6 to a 2mL centrifuge tube in order to control the total volume of the liquid in the centrifuge tube The concentration of Tris-HCl (pH8.0) in the centrifuge tube is 100mM, the concentration of MgCl 2 is 5mM, the concentration of ATP is 500μM, the concentration of IAA is 100μM, the concentration of aspartic acid is 1mM, GH3-6 The concentration was 14 μg/mL, and cultured at 30°C for 10 minutes;

2)显色反应:向2mL的离心管中依次加入50μL21mM钼酸铵试剂、200μL步骤1)得到的酶催化反应液、50μL0.5M2-巯基乙醇、20μLEikonogen试剂(含21mM亚硫酸钠、0.77M的焦亚硫酸钠、10.4M1-氨基-2-萘酚-4-磺酸)、室温下平衡反应30min后,测定其580nm条件下吸光度。2) Color reaction: Add 50 μL of 21 mM ammonium molybdate reagent, 200 μL of the enzyme-catalyzed reaction solution obtained in step 1), 50 μL of 0.5M 2-mercaptoethanol, and 20 μL of Eikonogen reagent (containing 21 mM sodium sulfite, 0.77 M sodium metabisulfite) into a 2 mL centrifuge tube in sequence. , 10.4M 1-amino-2-naphthol-4-sulfonic acid), after equilibrating at room temperature for 30 minutes, measure its absorbance at 580 nm.

本发明的酶抑制剂对于GH3-6的IC50分别为16.00±1.80、0.45±0.02μM,具有较好的酶抑制活性,在农药等领域显示潜在的应用前景。本发明酶抑制剂的制备方法简单,无需特殊反应条件,在常温常压下反应,后处理简便,产物收率较高。The IC 50 of the enzyme inhibitor of the present invention for GH3-6 is 16.00±1.80 and 0.45±0.02 μM respectively, has good enzyme inhibitory activity, and shows potential application prospects in fields such as pesticides. The preparation method of the enzyme inhibitor of the present invention is simple, does not need special reaction conditions, reacts at normal temperature and pressure, has simple post-treatment and high product yield.

四、具体实施方式4. Specific implementation

实施例1:Example 1:

1)羧基的活化1) Activation of the carboxyl group

在氮气保护下,向200mL的圆底烧瓶中加入苯丙酸(0.6g,4.0mmol)以及CDI(0.72g,4.45mmol),然后用针头向烧瓶内注入约50mL干燥乙腈,氮气保护约20min,密闭条件下室温反应1-2h,得到中间体1,制备得到的中间体1不用分离即可直接用于下一步反应。Under nitrogen protection, add phenylpropionic acid (0.6g, 4.0mmol) and CDI (0.72g, 4.45mmol) in the round bottom flask of 200mL, inject about 50mL dry acetonitrile in the flask with needle then, nitrogen protection about 20min, React at room temperature for 1-2 h under airtight conditions to obtain intermediate 1, which can be directly used in the next reaction without isolation.

2)偶联2) Coupling

向步骤1)制得的反应液中加入ASA中间体(1.4g,3.64mmol),溶液变浑浊,在冰水浴的条件下向反应液中加入1mLDBU(约6.58mmol),溶液变澄清,室温密闭条件下反应8-12h,薄层色谱(TLC)检测显示反应结束后减压蒸馏脱除溶剂,得到白色固体。向得到的白色固体中加入150mLCHCl3溶解,再加入150mL质量浓度3%的柠檬酸溶液洗涤,分离收集有机相,重复该过程2-3次,合并有机相;有机相依次用水和饱和食盐水洗涤后经无水硫酸钠干燥,减压蒸馏脱除有机溶剂,随后过硅胶柱(以体积比CHCl3/MeOH=10:1作为流动相)分离得到中间体2(1.69g,收率81.8%)。Add ASA intermediate (1.4g, 3.64mmol) to the reaction solution prepared in step 1), the solution becomes turbid, and 1mL DBU (about 6.58mmol) is added to the reaction solution under the condition of ice-water bath, the solution becomes clear and sealed at room temperature The reaction was carried out under the conditions for 8-12 hours, and thin layer chromatography (TLC) detection showed that after the reaction was completed, the solvent was distilled off under reduced pressure to obtain a white solid. Add 150mL CHCl to the obtained white solid to dissolve, then add 150mL of 3 % citric acid solution to wash, separate and collect the organic phase, repeat this process 2-3 times, combine the organic phase; wash the organic phase with water and saturated brine in turn After drying over anhydrous sodium sulfate, the organic solvent was removed by distillation under reduced pressure, and then separated by silica gel column (using volume ratio CHCl 3 /MeOH=10:1 as mobile phase) to obtain intermediate 2 (1.69 g, yield 81.8%) .

3)脱保护基3) deprotection group

将中间体2(0.78g,1.52mmol)加入到20mL质量浓度80%的HCOOH水溶液中,反应液透明,室温下反应至TLC检测反应结束,减压脱除溶剂得白色固体,以丙酮重结晶后得到目标产物(0.54g,收率75.9%);Intermediate 2 (0.78g, 1.52mmol) was added to 20mL of HCOOH aqueous solution with a mass concentration of 80%. The reaction solution was transparent and reacted at room temperature until the reaction was detected by TLC. The solvent was removed under reduced pressure to obtain a white solid, which was recrystallized from acetone. Obtain target product (0.54g, yield 75.9%);

所述以丙酮重结晶的具体过程如下:Described concrete process with acetone recrystallization is as follows:

将减压脱除溶剂后得到的白色固体加入烧瓶中,加入丙酮,加热至回流状态并不断添加新的丙酮,直至白色固体不再溶解,趁热过滤,滤液在冰水浴的条件下静置结晶,过滤、洗涤并干燥后即得目标产物。Put the white solid obtained after removing the solvent under reduced pressure into a flask, add acetone, heat to reflux and continuously add new acetone until the white solid is no longer dissolved, filter while it is hot, and the filtrate crystallizes in an ice-water bath , filtered, washed and dried to obtain the target product.

所述目标产物的结构式为:The structural formula of the target product is:

本实施例制备的酶抑制剂对GH3-6的酶活性抑制效果测试步骤如下:The enzyme inhibitors prepared in this example have the following steps for testing the inhibitory effect on the enzyme activity of GH3-6:

1)酶催化反应:向2mL的离心管中依次加入Tris-HCl(pH8.0)、MgCl2、ATP、IAA、天冬氨酸、酶抑制剂以及GH3-6,控制离心管内液体的总体积为1mL,离心管中Tris-HCl(pH8.0)的浓度为100mM,MgCl2的浓度为5mM、ATP的浓度为500μM、IAA的浓度为100μM、天冬氨酸的浓度为1mM、GH3-6的浓度为14μg/mL,在30℃的条件下培养10min;1) Enzyme-catalyzed reaction: Add Tris-HCl (pH8.0), MgCl 2 , ATP, IAA, aspartic acid, enzyme inhibitors and GH3-6 to a 2mL centrifuge tube in order to control the total volume of the liquid in the centrifuge tube The concentration of Tris-HCl (pH8.0) in the centrifuge tube is 100mM, the concentration of MgCl 2 is 5mM, the concentration of ATP is 500μM, the concentration of IAA is 100μM, the concentration of aspartic acid is 1mM, GH3-6 The concentration was 14 μg/mL, and cultured at 30°C for 10 minutes;

2)显色反应:向2mL的离心管中先后加入50μL21mM钼酸铵试剂、200μL步骤1)得到的酶催化反应液、50μL0.5M2-巯基乙醇、20μLEikonogen试剂(含21mM亚硫酸钠、0.77M的焦亚硫酸钠、10.4M1-氨基-2-萘酚-4-磺酸),室温下平衡反应30min后,测定其580nm条件下吸光度。2) Color reaction: Add 50 μL of 21 mM ammonium molybdate reagent, 200 μL of the enzyme-catalyzed reaction solution obtained in step 1), 50 μL of 0.5M 2-mercaptoethanol, and 20 μL of ikonogen reagent (containing 21 mM sodium sulfite, 0.77 M sodium metabisulfite) into a 2 mL centrifuge tube successively. , 10.4M 1-amino-2-naphthol-4-sulfonic acid), after equilibrating at room temperature for 30 minutes, measure its absorbance at 580 nm.

经过测定,本实施例制备的酶抑制剂对于GH3-6的IC50为16.00±1.80μM,显示了较好的酶抑制活性。It was determined that the IC 50 of the enzyme inhibitor prepared in this example for GH3-6 was 16.00±1.80 μM, showing good enzyme inhibitory activity.

实施例2:Example 2:

1)羧基的活化1) Activation of the carboxyl group

在氮气保护下,向200mL的圆底烧瓶中加入萘甲酸(0.50g,2.90mmol)以及CDI(0.56g,3.43mmol),然后用针头向烧瓶内注入约50mL干燥乙腈,氮气保护约20min,密闭条件下室温反应1-2h,得到中间体1,制备得到的中间体1不用分离即可直接用于下一步反应。Under nitrogen protection, add naphthoic acid (0.50g, 2.90mmol) and CDI (0.56g, 3.43mmol) into a 200mL round bottom flask, then inject about 50mL of dry acetonitrile into the flask with a needle, nitrogen protection for about 20min, airtight Under the condition of room temperature reaction for 1-2h, the intermediate 1 is obtained, and the prepared intermediate 1 can be directly used in the next reaction without isolation.

2)偶联2) Coupling

向步骤1)制得的反应液中加入ASA中间体(1.02g,2.64mmol),溶液变浑浊,在冰水浴的条件下向反应液中加入0.68mLDBU(约4.47mmol),溶液变澄清,室温密闭条件下反应8-12h,薄层色谱(TLC)检测显示反应结束后减压蒸馏脱除溶剂,得到白色固体。向得到的白色固体中加入150mLCHCl3溶解,再加入150mL质量浓度3%的柠檬酸溶液洗涤,分离收集有机相,重复该过程2-3次,合并有机相;有机相依次用水和饱和食盐水洗涤后经无水硫酸钠干燥,减压蒸馏脱除有机溶剂,随后过硅胶柱(以体积比CHCl3/MeOH=12:1作为流动相)分离得到中间体2(1.07g,收率75.4%)。Add ASA intermediate (1.02g, 2.64mmol) to the reaction solution prepared in step 1), the solution becomes turbid, and 0.68mLDBU (about 4.47mmol) is added to the reaction solution under the condition of an ice-water bath, the solution becomes clear, room temperature The reaction was carried out under airtight conditions for 8-12 hours. Thin layer chromatography (TLC) detection showed that after the reaction was completed, the solvent was distilled off under reduced pressure to obtain a white solid. Add 150mL CHCl to the obtained white solid to dissolve, then add 150mL of 3 % citric acid solution to wash, separate and collect the organic phase, repeat this process 2-3 times, combine the organic phase; wash the organic phase with water and saturated brine in turn After drying over anhydrous sodium sulfate, the organic solvent was removed by distillation under reduced pressure, and then separated by silica gel column (using volume ratio CHCl 3 /MeOH=12:1 as mobile phase) to obtain intermediate 2 (1.07g, yield 75.4%) .

3)脱保护基3) deprotection group

将中间体2(1.07g,1.98mmol)加入到30mL质量浓度80%的HCOOH水溶液中,反应液透明,室温下反应至TLC检测反应结束,反应结束后减压脱除溶剂得白色固体,以丙酮重结晶后得到目标产物(0.82g,收率82.5%);Intermediate 2 (1.07g, 1.98mmol) was added to 30mL of HCOOH aqueous solution with a mass concentration of 80%, the reaction solution was transparent, and reacted at room temperature until the reaction was detected by TLC. After the reaction was completed, the solvent was removed under reduced pressure to obtain a white solid. The target product (0.82g, yield 82.5%) was obtained after recrystallization;

所述以丙酮重结晶的具体过程如下:Described concrete process with acetone recrystallization is as follows:

将减压脱除溶剂后得到的白色固体加入烧瓶中,加入丙酮,加热至回流状态并不断添加新的丙酮,直至白色固体全部溶解,趁热过滤,滤液在冰水浴的条件下静置结晶,过滤、洗涤并干燥后即得目标产物。Put the white solid obtained after removing the solvent under reduced pressure into the flask, add acetone, heat to reflux and add new acetone until the white solid is completely dissolved, filter while it is hot, and the filtrate is left to crystallize under the condition of an ice-water bath. The target product was obtained after filtration, washing and drying.

所述目标产物的结构式为:The structural formula of the target product is:

本实施例制备的酶抑制剂对GH3-6的酶活性抑制效果测试步骤如下:The enzyme inhibitors prepared in this example have the following steps for testing the inhibitory effect on the enzyme activity of GH3-6:

1)酶催化反应:向2mL的离心管中依次加入Tris-HCl(pH8.0)、MgCl2、ATP、IAA、天冬氨酸、酶抑制剂以及GH3-6,控制离心管内液体的总体积为1mL,离心管中Tris-HCl(pH8.0)的浓度为100mM,MgCl2的浓度为5mM、ATP的浓度为500μM、IAA的浓度为100μM、天冬氨酸的浓度为1mM、GH3-6的浓度为14μg/mL,在30℃的条件下培养10min;1) Enzyme-catalyzed reaction: Add Tris-HCl (pH8.0), MgCl 2 , ATP, IAA, aspartic acid, enzyme inhibitors and GH3-6 to a 2mL centrifuge tube in order to control the total volume of the liquid in the centrifuge tube The concentration of Tris-HCl (pH8.0) in the centrifuge tube is 100mM, the concentration of MgCl 2 is 5mM, the concentration of ATP is 500μM, the concentration of IAA is 100μM, the concentration of aspartic acid is 1mM, GH3-6 The concentration was 14 μg/mL, and cultured at 30°C for 10 minutes;

2)显色反应:向2mL的离心管中先后加入50μL21mM钼酸铵试剂、200μL步骤1)得到的酶催化反应液、50μL0.5M2-巯基乙醇、20μLEikonogen试剂(含21mM亚硫酸钠、0.77M的焦亚硫酸钠、10.4M1-氨基-2-萘酚-4-磺酸),室温下平衡反应30min后,测定其580nm条件下吸光度。2) Color reaction: Add 50 μL of 21 mM ammonium molybdate reagent, 200 μL of the enzyme-catalyzed reaction solution obtained in step 1), 50 μL of 0.5M 2-mercaptoethanol, and 20 μL of ikonogen reagent (containing 21 mM sodium sulfite, 0.77 M sodium metabisulfite) into a 2 mL centrifuge tube successively. , 10.4M 1-amino-2-naphthol-4-sulfonic acid), after equilibrating at room temperature for 30 minutes, measure its absorbance at 580 nm.

经过测定,本实施例制备的酶抑制剂对于GH3-6的IC50为0.45±0.02μM,显示了较好的酶抑制活性。After determination, the enzyme inhibitor prepared in this example has an IC 50 of 0.45±0.02 μM for GH3-6, showing a good enzyme inhibitory activity.

Claims (7)

1., based on an ASA type enzyme inhibitors of plant hormone regulatory gene GH3, it is characterized in that its structural formula is:
Wherein R is styroyl or naphthyl.
2. a preparation method for the ASA type enzyme inhibitors based on plant hormone regulatory gene GH3 according to claim 1, is characterized in that comprising the following steps:
1) activation of carboxyl
Under nitrogen protection, be dissolved in organic solvent by carboxylic acid and carboxyl activator, confined reaction 1-2h under room temperature, obtains intermediate 1;
Mol ratio between described carboxylic acid and described carboxyl activator is 1:1.1-1.3;
The structural formula of described intermediate 1 is:
R is styroyl or naphthyl;
2) coupling
To step 1) add ASA intermediate in obtained reaction solution, in the condition downhill reaction liquid of ice-water bath, add 1,8-diazacyclo [5.4.0] 11 carbon-7-alkene, react 8-12h under room temperature air tight condition, after separation and purification, obtain intermediate 2;
Mol ratio in reaction solution between intermediate 1, ASA intermediate and 1,8-diazacyclo [5.4.0] 11 carbon-7-alkene is: 1:1:1.8-2.5;
The structural formula of described ASA intermediate is:
The structural formula of described intermediate 2 is:
R is styroyl or naphthyl;
3) Deprotection
Added by intermediate 2 in Deprotection reagent solution, react 1.5-2.5h under room temperature, reaction terminates rear removed under reduced pressure solvent, to obtain target product after acetone recrystallization.
3. preparation method according to claim 2, is characterized in that:
Step 1) described in carboxylic acid be phenylpropionic acid or naphthoic acid; Described carboxyl activator is carbonyl dimidazoles.
4. preparation method according to claim 2, is characterized in that:
Step 1) described in organic solvent be the methylene dichloride of anhydrous acetonitrile, DMF, methyl-sulphoxide or drying.
5. preparation method according to claim 2, is characterized in that:
Step 2) described in the detailed process of separation and purification as follows:
By reaction solution underpressure distillation desolvation after reaction terminates, then add CHCl 3dissolve, then add the citric acid solution washing of mass concentration 3%, separated and collected organic phase, through anhydrous sodium sulfate drying after organic phase washed with water and saturated common salt water washing, underpressure distillation removes CHCl 3, cross silicagel column separation subsequently and obtain intermediate 2.
6. preparation method according to claim 2, is characterized in that:
Step 3) described in Deprotection reagent solution be the HCOOH aqueous solution of mass concentration 80%, the 5-10% hydrochloric acid soln of mass concentration or trifluoroacetic acid.
7. preparation method according to claim 2, is characterized in that:
Step 3) described in as follows with the detailed process of acetone recrystallization:
The white solid obtained after removed under reduced pressure solvent is added in flask, adds acetone, be heated to reflux state and constantly add new acetone, until white solid no longer dissolves, filtered while hot, filtrate leaves standstill crystallization under the condition of ice-water bath, filters, washs and namely obtain target product after drying.
CN201410422288.1A 2014-08-25 2014-08-25 An ASA-type enzyme inhibitor based on auxin-regulated gene GH3 and preparation method thereof Active CN104177361B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410422288.1A CN104177361B (en) 2014-08-25 2014-08-25 An ASA-type enzyme inhibitor based on auxin-regulated gene GH3 and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410422288.1A CN104177361B (en) 2014-08-25 2014-08-25 An ASA-type enzyme inhibitor based on auxin-regulated gene GH3 and preparation method thereof

Publications (2)

Publication Number Publication Date
CN104177361A CN104177361A (en) 2014-12-03
CN104177361B true CN104177361B (en) 2016-03-30

Family

ID=51958736

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410422288.1A Active CN104177361B (en) 2014-08-25 2014-08-25 An ASA-type enzyme inhibitor based on auxin-regulated gene GH3 and preparation method thereof

Country Status (1)

Country Link
CN (1) CN104177361B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824657A (en) * 1997-03-18 1998-10-20 Cubist Pharmaceuticals, Inc. Aminoacyl sulfamides for the treatment of hyperproliferative disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113615A2 (en) * 2005-04-15 2006-10-26 Sloan-Kettering Institute For Cancer Research Anti-microbial agents and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824657A (en) * 1997-03-18 1998-10-20 Cubist Pharmaceuticals, Inc. Aminoacyl sulfamides for the treatment of hyperproliferative disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
The synthesis of nucleoside sulfamates related to nucleocidin;Shuman DA et al.;《Journal of the American Chemical Society》;19700603;第92卷(第11期);第3434-3440页 *
孙涛等.植物GH3基因家族研究进展.《生物工程学报》.2008,第24卷(第11期),第1860-1866页. *

Also Published As

Publication number Publication date
CN104177361A (en) 2014-12-03

Similar Documents

Publication Publication Date Title
Sheehan et al. The synthesis of stereochemically pure peptide derivatives by the phthaloyl method
CN107903260B (en) A kind of indoles and dihydropyridine ketone compound and its crystal form and preparation method
CN104177361B (en) An ASA-type enzyme inhibitor based on auxin-regulated gene GH3 and preparation method thereof
BRPI0520822B1 (en) process of increasing the number of inflorescences
RU2196772C1 (en) 6-methyl-8-methoxymethyl-3-phenylisoxazolo-[3',4':4,5]-thieno[2,3-b]pyridine eliciting growth regulating and antistress activity
CN113072544B (en) Indole-3-carboxylic acid-based compound capable of promoting germination of parasitic plant seeds and preparation method thereof
JPS62135491A (en) Aromatic sulfonate salt of proline derivative
CN106699586B (en) The preparation method of aspartic acid ornithine
CN103173423A (en) Method for extracting superoxide dismutase with high yield from corn
WO2023115742A1 (en) Brassinosteroid analog, new crystal form, preparation method, and use
CN109111428A (en) A kind of dextro-rabeprazole sodium compound and pharmaceutical composition thereof
CN103467552B (en) 8-cyclohexyl-2-fluoro-vidarabine as well as preparation method and application thereof
WO2023115741A1 (en) Novel brassinosteroid analogue, novel crystalline form and preparation method therefor and application thereof
CN113683653A (en) Adenosine crystal form, preparation method and application thereof
US4148994A (en) Crystalline metal salts of β-nicotinamide-adenine-dinucleotide
CN107266407A (en) A kind of nitroreductase that responds kills photaesthesia targeting anti-tumor prodrug of tumour cell and preparation method and application
CN102180883B (en) Substituted porphyrin gold (III) compounds with anticancer activity and preparation method thereof
CN106349145A (en) Method for preparing intelligence-improving medicine (S)-oxiracetam
CN105753937A (en) Synthesis method for marine cyclopeptide compound 27-Deoxylyngbyabellin A and derivative of marine cyclopeptide compound 27-Deoxylyngbyabellin A
CN107266434B (en) Phenanthroindolizidine alkaloid 6-position derivative, preparation thereof, plant virus resisting activity and anticancer activity
CN106061988A (en) Crystalline 3',5'-cyclic diguanylic acid
CN104496992B (en) Model compound for the research of blue light receptor photo induced electron transfer and preparation method thereof
CN116239500B (en) High-activity abscisic acid functional analogue (I) and preparation method thereof
CN110642816A (en) Crystalline 3-O-ethyl vitamin C and preparation method and application thereof
CN114920793B (en) Estrone compound containing isopropanolamine substructure, preparation method, composition and application

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant